Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel
NASDAQ:UNCY

Unicycive Therapeutics Q3 2026 Earnings Date & Estimates

Unicycive Therapeutics logo
$3.73 -0.32 (-7.90%)
Closing price 10/13/2026 04:00 PM Eastern
Extended Trading
$3.75 +0.02 (+0.59%)
As of 10/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Unicycive Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Unicycive Therapeutics in Q3 2026

Unicycive Therapeutics is expected to post earnings of -$0.33 per share on revenue of $0.90 million. In the same quarter a year earlier Unicycive Therapeutics reported -$0.39 per share. Unicycive Therapeutics last reported on August 12, 2026, posting -$0.06 per share and beating the -$0.4710 consensus estimate. Unicycive Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.33
Expected Revenue
$0.90 million
Prior-Year EPS
-$0.39

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.06 (Beat by +$0.4110)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Unicycive Therapeutics Q3 2026 Earnings FAQ

Unicycive Therapeutics (NASDAQ:UNCY) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Unicycive Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Unicycive Therapeutics to post earnings of -$0.33 per share for Q3 2026.

The consensus revenue estimate for Unicycive Therapeutics is $0.90 million for Q3 2026.

Unicycive Therapeutics Earnings Headlines

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
October 13 at 7:39 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/unicycive-deadline-uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302907557.html
UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt
October 13 at 1:51 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3380058/0/en/uncy-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-unicycive-therapeutics-securities-lawsuit-contact-suewallst.html
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.tc pixel
 |  Paradigm Press (Ad)
Kaplan Fox & Kilsheimer LLP Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to the Lead Plaintiff Deadline on November 2, 2026
October 13 at 7:26 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UNCY/pressreleases/6173755/kaplan-fox-kilsheimer-llp-alerts-unicycive-therapeutics-inc-nasdaq-uncy-investors-to-the-lead-plaintiff-deadline-on-november-2-2026/
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
October 12 at 1:49 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/12/3379158/3080/en/uncy-shareholder-alert-november-2-2026-lead-plaintiff-deadline-in-unicycive-therapeutics-inc-securities-class-action-contact-levi-korsinsky.html
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
October 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302902953.html
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY) (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease. The company’s primary focus is hyperphosphatemia, a condition in which phosphate levels become abnormally high in patients with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream. The company is developing OLC as a potential treatment option for patients with chronic kidney disease who require dialysis and need ongoing phosphate management.

The company’s activities are primarily focused on advancing OLC through clinical development and regulatory processes, initially in the United States. Unicycive is headquartered in the United States and is led by Chief Executive Officer Shalabh Gupta, M.D.

View Unicycive Therapeutics Profile
Earnings Tools